Skip to content

Peptides, hormones and pipeline drugs

Mazdutide

Mazdutide is a weekly glucagon and GLP-1 dual agonist approved in China in 2025 for weight management. It is not approved by the FDA in the US.

Clinician review pending Updated Peptides, hormones and pipeline drugs
DefinitionMazdutide is a weekly glucagon and GLP-1 dual agonist approved in China in 2025 for weight management. It is not approved by the FDA in the US.

What it means

Mazdutide was discovered by Eli Lilly and licensed to Innovent Biologics for China. Like survodutide, it activates both the GLP-1 and glucagon receptors, and it is often described as an analog of oxyntomodulin, a natural gut hormone that does the same.

China's drug regulator approved it in June 2025 for chronic weight management in adults with obesity, or overweight with a weight-related condition. The approval was based on the GLORY-1 trial in Chinese adults, published in NEJM in 2025.

Mazdutide is not FDA-approved. The FDA has named mazdutide among GLP-1-type products being sold online in the US labeled "for research purposes" or "not for human consumption." Products like these have no FDA review of their contents or quality.

Side effects in trials were mostly stomach-related, similar to other drugs in the class.

Why it matters

A drug approved in another country is still unapproved in the US, and US products sold under its name carry real quality risks.

Related terms

OxyntomodulinGlucagon receptor agonistSurvodutideResearch peptides ("not for human use")

Sources

  1. GLORY-1 trial (NEJM, 2025)
  2. FDA: Concerns with unapproved GLP-1 drugs

Clinician review pending. Drafted from primary sources and waiting for sign-off by a licensed clinician (MD, DO or PharmD) before launch. Every number is checked against its source. Drug facts are re-checked quarterly, prices monthly and whenever a label changes. How we review · Report an error